PL353539A1 - Pochodne N-heterocykliczne jako inhibitory NOS (syPochodne N-heterocykliczne jako inhibitory NOS (syntazy tlenku azotu)ntazy tlenku azotu) - Google Patents

Pochodne N-heterocykliczne jako inhibitory NOS (syPochodne N-heterocykliczne jako inhibitory NOS (syntazy tlenku azotu)ntazy tlenku azotu)

Info

Publication number
PL353539A1
PL353539A1 PL00353539A PL35353900A PL353539A1 PL 353539 A1 PL353539 A1 PL 353539A1 PL 00353539 A PL00353539 A PL 00353539A PL 35353900 A PL35353900 A PL 35353900A PL 353539 A1 PL353539 A1 PL 353539A1
Authority
PL
Poland
Prior art keywords
heterocyclic derivatives
nos inhibitors
inhibitors
compounds
nitric oxide
Prior art date
Application number
PL00353539A
Other languages
English (en)
Inventor
Damian O.Arnaiz Damian O. Arnaiz
John J.Baldwin John J. Baldwin
David D.Davey David D. Davey
James J.Devlin James J. Devlin
Roland Ellwood IIIDolle Roland Ellwood Dolle III
Shawn DavidErickson Shawn David Erickson
KirkMcMillan Kirk McMillan
Michael M.Morrissey Michael M. Morrissey
Michael H.J.Ohlmeyer Michael H.J. Ohlmeyer
GonghuaPan Gonghua Pan
Vidyadhar MadhavParadkar Vidyadhar Madhav Paradkar
JohnParkinson John Parkinson
Gary B.Phillips Gary B. Phillips
BinYe Bin Ye
ZuchunZhao Zuchun Zhao
Original Assignee
Berlex Laboratories, Inc.Berlex Laboratories, Inc.
Pharmacopeia, Inc.Pharmacopeia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Laboratories, Inc.Berlex Laboratories, Inc., Pharmacopeia, Inc.Pharmacopeia, Inc. filed Critical Berlex Laboratories, Inc.Berlex Laboratories, Inc.
Publication of PL353539A1 publication Critical patent/PL353539A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
PL00353539A 1999-08-26 2000-08-24 Pochodne N-heterocykliczne jako inhibitory NOS (syPochodne N-heterocykliczne jako inhibitory NOS (syntazy tlenku azotu)ntazy tlenku azotu) PL353539A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/383,813 US6432947B1 (en) 1997-02-19 1999-08-26 N-heterocyclic derivatives as NOS inhibitors
PCT/US2000/023173 WO2001014371A1 (en) 1999-08-26 2000-08-24 N-heterocyclic derivatives as nos inhibitors

Publications (1)

Publication Number Publication Date
PL353539A1 true PL353539A1 (pl) 2003-12-01

Family

ID=23514822

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00353539A PL353539A1 (pl) 1999-08-26 2000-08-24 Pochodne N-heterocykliczne jako inhibitory NOS (syPochodne N-heterocykliczne jako inhibitory NOS (syntazy tlenku azotu)ntazy tlenku azotu)

Country Status (34)

Country Link
US (11) US6432947B1 (pl)
EP (1) EP1206467B1 (pl)
JP (1) JP4739625B2 (pl)
KR (1) KR100708783B1 (pl)
CN (1) CN1206228C (pl)
AT (1) ATE256681T1 (pl)
AU (1) AU769405B2 (pl)
BG (1) BG65804B1 (pl)
BR (1) BR0014144A (pl)
CA (1) CA2376355C (pl)
CZ (1) CZ2002642A3 (pl)
DE (1) DE60007329T2 (pl)
DK (1) DK1206467T3 (pl)
EE (1) EE05199B1 (pl)
ES (1) ES2213599T3 (pl)
HK (2) HK1043594A1 (pl)
HR (1) HRP20020175B1 (pl)
HU (1) HUP0202450A3 (pl)
IL (2) IL148313A0 (pl)
LT (1) LT4982B (pl)
LV (1) LV12887B (pl)
MX (1) MXPA02002022A (pl)
NO (1) NO323886B1 (pl)
NZ (1) NZ517411A (pl)
PL (1) PL353539A1 (pl)
PT (1) PT1206467E (pl)
RO (1) RO122202B1 (pl)
RS (1) RS50378B (pl)
RU (1) RU2277094C2 (pl)
SI (1) SI20818B (pl)
SK (1) SK2622002A3 (pl)
UA (1) UA72930C2 (pl)
WO (1) WO2001014371A1 (pl)
ZA (1) ZA200201485B (pl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
CA2379064A1 (en) * 1999-07-15 2001-01-25 Pharmacopeia, Inc. Bradykinin b1 receptor antagonists
GB2361473C (en) * 2000-03-08 2005-06-28 Microgenics Corp Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
CA2404023A1 (en) * 2000-04-03 2001-10-11 Richard E. Olson Cyclic lactams as inhibitors of a.beta. protein production
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
US8571653B2 (en) * 2001-08-31 2013-10-29 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
US7885709B2 (en) * 2001-08-31 2011-02-08 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation for treating disorders
US7904176B2 (en) 2006-09-07 2011-03-08 Bio Control Medical (B.C.M.) Ltd. Techniques for reducing pain associated with nerve stimulation
US7778711B2 (en) * 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
EP1795192A3 (en) * 2002-04-30 2008-05-07 Bayer Schering Pharma Aktiengesellschaft 1-(Pyridazin-3-yl)-imidazole derivatives as inhibitors of nitric oxide synthase (NOS)
WO2004019986A1 (en) * 2002-08-29 2004-03-11 Schering Aktiengesellschaft Methods of treating acute respiratory distress syndrome
JP2006506366A (ja) * 2002-10-18 2006-02-23 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用方法
AU2005214319B2 (en) * 2004-02-12 2009-02-19 Merck Sharp & Dohme Corp. Amino heterocyclic modulators of chemokine receptor activity
EP1568698A1 (en) * 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
KR100935273B1 (ko) * 2004-06-10 2010-01-06 아이알엠 엘엘씨 단백질 키나제 억제제 화합물 및 조성물
MY144044A (en) * 2004-06-10 2011-07-29 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1796673A2 (en) * 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
WO2006055831A2 (en) * 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
US20070123572A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines
BRPI0518096A (pt) * 2004-12-01 2008-10-28 Kalypsys Inc composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
RU2007140903A (ru) * 2005-04-05 2009-05-20 Фармакопия, Инк. (Us) Производные пурина и имидазопиридина для иммуносупрессии
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
CA2618653A1 (en) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
KR20080070822A (ko) * 2005-11-28 2008-07-31 칼립시스, 인코포레이티드 유도가능 산화질소 신타제 이량체화 억제제의 염
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
JP2009534454A (ja) * 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
DK3421471T3 (da) * 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
HUE046709T2 (hu) 2006-10-03 2020-03-30 Genzyme Corp Génterápia amiotrófiás laterálszklerózis és más gerincvelõi rendellenességek kezelésére
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
CL2007002866A1 (es) * 2006-10-04 2008-07-04 Pharmacopeia Inc Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
US7915268B2 (en) * 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
EP1939181A1 (en) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
CA2683152A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
MY150059A (en) 2007-10-11 2013-11-29 Astrazeneca Ab Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
WO2009097475A1 (en) * 2008-01-30 2009-08-06 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
US20100311776A1 (en) * 2008-01-30 2010-12-09 Smithkline Beecham Corporation Novel sEH Inhibitors and their Use
US20100324076A1 (en) * 2008-01-30 2010-12-23 Joseph Paul Marino Novel sEH Inhibitors and their Use
JP2011515462A (ja) * 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
EP2477826B1 (en) 2009-09-18 2016-06-01 Volvo Lastvagnar AB Console for attachment to a vehicle chassis and vehicle comprising a suspension carrying console
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
CN102617503B (zh) * 2011-03-03 2014-05-07 上海常丰生物医药科技有限公司 (s)-3-吗啉基羧酸的合成方法
EP2694056B1 (en) 2011-04-01 2019-10-16 AstraZeneca AB Therapeutic treatment
WO2013079964A1 (en) 2011-11-30 2013-06-06 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US9701661B2 (en) * 2014-07-11 2017-07-11 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds
EP3558997B1 (en) 2016-12-20 2021-01-27 AstraZeneca AB Amino-triazolopyridine compounds and their use in treating cancer
CN107115334A (zh) * 2017-03-04 2017-09-01 王宏 一种治疗免疫性流产的药物组合物
IL277495B1 (en) 2018-03-23 2024-04-01 Carmot Therapeutics Inc Modulators of protein-coupled receptors - G

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339875A (ja) 1986-08-05 1988-02-20 Nissin Food Prod Co Ltd ピリミジン誘導体
DE4118720A1 (de) 1991-06-07 1992-12-10 Bayer Ag Substituierte imidazolinylpyrimidine
TW212798B (pl) * 1991-11-25 1993-09-11 Takeda Pharm Industry Co Ltd
WO1993017009A1 (en) * 1992-02-28 1993-09-02 Zenyaku Kogyo Kabushiki Kaisha s-TRIAZINE DERIVATIVE AND REMEDY FOR ESTROGEN-DEPENDENT DISEASES CONTAINING THE SAME AS ACTIVE INGREDIENT
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
DE69408750T2 (de) 1993-08-26 1998-07-23 Ono Pharmaceutical Co 4-Aminopyrimidin Derivate
US5426110A (en) 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
AU4149696A (en) 1994-11-15 1996-06-06 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase
ATE236161T1 (de) * 1995-11-01 2003-04-15 Novartis Pharma Gmbh Purinderivate und verfahren zu ihrer herstellung
ZA977427B (en) 1996-09-04 1998-03-02 Dainippon Pharmaceutical Co 2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same.
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
JP4495257B2 (ja) * 1997-02-19 2010-06-30 バーレツクス ラボラトリーズ インコーポレーテツド Ｎｏｓ抑制剤としてのｎ−複素環誘導体
US6172005B1 (en) * 1997-03-11 2001-01-09 E. I. Du Pont De Nemours And Company Heteroaryl azole herbicides
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors

Also Published As

Publication number Publication date
HK1051683A1 (en) 2003-08-15
US6841674B2 (en) 2005-01-11
US20020183323A1 (en) 2002-12-05
RS50378B (sr) 2009-11-10
US6670473B2 (en) 2003-12-30
US20030083332A1 (en) 2003-05-01
WO2001014371A1 (en) 2001-03-01
US20030069210A1 (en) 2003-04-10
US6864368B2 (en) 2005-03-08
EP1206467A1 (en) 2002-05-22
HK1043594A1 (zh) 2002-09-20
US20030092678A1 (en) 2003-05-15
CZ2002642A3 (cs) 2002-08-14
HRP20020175B1 (en) 2008-07-31
US6841673B2 (en) 2005-01-11
NO323886B1 (no) 2007-07-16
ES2213599T3 (es) 2004-09-01
US6849739B2 (en) 2005-02-01
SI20818A (sl) 2002-08-31
LT4982B (lt) 2003-01-27
DE60007329D1 (de) 2004-01-29
AU769405B2 (en) 2004-01-29
YU12002A (sh) 2005-03-15
US20030027794A1 (en) 2003-02-06
MXPA02002022A (es) 2002-10-31
KR100708783B1 (ko) 2007-04-19
CN1206228C (zh) 2005-06-15
CN1382136A (zh) 2002-11-27
US20030004137A1 (en) 2003-01-02
ZA200201485B (en) 2003-07-30
IL148313A0 (en) 2002-09-12
US20030078265A1 (en) 2003-04-24
AU7067100A (en) 2001-03-19
DE60007329T2 (de) 2004-06-09
KR20020062277A (ko) 2002-07-25
ATE256681T1 (de) 2004-01-15
US6864263B2 (en) 2005-03-08
BG106440A (en) 2002-11-29
JP4739625B2 (ja) 2011-08-03
RU2277094C2 (ru) 2006-05-27
NZ517411A (en) 2003-09-26
HUP0202450A3 (en) 2003-12-29
US6846829B2 (en) 2005-01-25
EE05199B1 (et) 2009-08-17
US6747031B2 (en) 2004-06-08
CA2376355A1 (en) 2001-03-01
LV12887B (en) 2003-01-20
US6887865B2 (en) 2005-05-03
US20030073669A1 (en) 2003-04-17
UA72930C2 (uk) 2005-05-16
NO20020925D0 (no) 2002-02-26
RO122202B1 (ro) 2009-02-27
SI20818B (sl) 2009-04-30
LT2002028A (en) 2002-09-25
HRP20020175A2 (en) 2005-10-31
DK1206467T3 (da) 2004-04-26
BG65804B1 (bg) 2009-12-31
EE200200091A (et) 2003-04-15
NO20020925L (no) 2002-04-16
JP2003507476A (ja) 2003-02-25
CA2376355C (en) 2009-10-27
EP1206467B1 (en) 2003-12-17
BR0014144A (pt) 2002-05-21
SK2622002A3 (en) 2002-09-10
US20030060452A1 (en) 2003-03-27
US6432947B1 (en) 2002-08-13
HUP0202450A2 (hu) 2002-11-28
IL148313A (en) 2008-04-13
PT1206467E (pt) 2004-05-31
US20020165203A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
HK1051683A1 (en) N-heterocyclic derivatives as nos inhibitors
GB2338957B (en) N-heterocyclic derivatives as nos inhibitors
HK1053834A1 (zh) 用作nos抑制劑的n-雜環衍生物
AU2002239344A1 (en) Pyrazolopyridines
AU2003228678A1 (en) 1-substituted imidazole derivatives as nos inhibitors
AU2002239348A1 (en) Pyrazolopyridine derivatives
AU2002248531A1 (en) Pyrazolopyriadine derivatives
WO2003080631A3 (en) Plasma carboxypeptidase b inhibitors
WO2004093796A3 (en) Lactam derivatives and methods of their use
EP1795192A3 (en) 1-(Pyridazin-3-yl)-imidazole derivatives as inhibitors of nitric oxide synthase (NOS)

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)